fosfomycin and Lymphoma

fosfomycin has been researched along with Lymphoma* in 2 studies

Other Studies

2 other study(ies) available for fosfomycin and Lymphoma

ArticleYear
[Clinical evaluation of a combination treatment with cefminox and fosfomycin for infections complicated in patients with hematological disorders].
    The Japanese journal of antibiotics, 1991, Volume: 44, Issue:11

    We evaluated clinical effects and toxicities of a combination treatment with cefminox (CMNX) and fosfomycin (FOM) for infections complicated with hematological disorders in 56 patients. Among those, 52 patients including 22 with malignant lymphoma, 19 with acute leukemia, and 11 with other hematological disorders were evaluable. Excellent and good responses were obtained in 33 (63.5%) of the 52 patients. This treatment was also effective in 5 of 9 cases in which granulocyte counts were less than 500/mm3 through the course of administration. Side effects were observed in only one patient. Mild nausea occurred but was not serious. These results indicate that the combination of CMNX and FOM is an effective and safe regimen for the treatment of infections complicated in patients with hematological disorders.

    Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Cephamycins; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fosfomycin; Hematologic Diseases; Humans; Immunocompromised Host; Infusions, Intravenous; Leukemia; Lymphoma; Male; Middle Aged

1991
[Clinical evaluation of high dose intravenous injection of fosfomycin on the severe infections associated with the treatment of haematological disorders].
    The Japanese journal of antibiotics, 1983, Volume: 36, Issue:2

    Fosfomycin (FOM) was administered intravenously to 65 cases of severe infections complicated with 62 cases of several haematological disorders. Out of 65 cases, 45 were treated with high doses FOM, i.e., 8 g per day or more. Another 20 cases were treated in usual doses of 4--6 g per day. Causative organisms were isolated from 52 cases of which 32 cases were Gram-negative bacilli and 19 cases were Gram-positive cocci. The effective rate of FOM was 57.8% in the high-dose treatment group (26/45) and 45.0% in the usual-dose treatment group (9/20), but the significant difference was not defined. Among 32 cases with Gram-negative bacilli infections, including Pseudomonas aeruginosa or Serratia marcescens, 15 cases were effective (47%). On the contrary, 14 out of 19 cases with Gram-positive cocci infections were effective (74%). Thirteen cases (50.0%) were effective even in which neutrophils were less than 500/cmm before FOM administration. Severe side effects were not observed, without 2 cases. One was skin eruption due to drug allergy and the other was suspected to be interstitial pneumonitis, but not confirmed pathologically. These data suggest that high dose treatment of FOM were useful for the severe infections even in neutropenic state in haematological disorders.

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Child; Female; Fosfomycin; Humans; Injections, Intravenous; Leukemia; Lymphoma; Male; Middle Aged

1983